Ironwood Pharmaceuticals, Inc.

DB:I76 Stock Report

Market Cap: €292.8m

Ironwood Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:I76 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Feb 25Sell€66,468John MinardoIndividual38,938€1.71
10 Feb 25Sell€20,573Greg MartiniIndividual12,052€1.71
10 Feb 25Sell€20,566Ronald SilverIndividual12,048€1.71
10 Feb 25Sell€70,447Michael ShetzlineIndividual41,269€1.71
10 Feb 25Sell€237,386Thomas McCourtIndividual139,064€1.71
18 Nov 24Sell€42,465Sravan EmanyIndividual11,001€3.86
18 Nov 24Sell€20,690Andrew DavisIndividual5,360€3.86
12 Aug 24Sell€12,133Ronald SilverIndividual3,107€3.90
12 Aug 24Sell€38,698John MinardoIndividual9,910€3.90
07 Jun 24Sell€478,970Catherine MoukheibirIndividual80,000€6.12
20 May 24Sell€103,354John MinardoIndividual17,404€5.94
20 May 24Sell€95,776Michael ShetzlineIndividual16,128€5.94
20 May 24Sell€401,551Thomas McCourtIndividual67,618€5.94
20 May 24Sell€134,953Andrew DavisIndividual22,725€5.94
06 Mar 24Buy€55,225Jon DuaneIndividual6,920€7.98
04 Mar 24Buy€92,269Sravan EmanyIndividual10,684€8.64

Insider Trading Volume

Insider Buying: I76 insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of I76?
Owner TypeNumber of SharesOwnership Percentage
State or Government64,8740.0391%
Individual Insiders3,163,6511.91%
Hedge Funds33,187,19820%
Institutions129,422,88378%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 84.48% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.4%
BlackRock, Inc.
23,037,335€42.2m0.51%no data
12.2%
The Vanguard Group, Inc.
19,538,555€35.8m-11.3%no data
10.2%
Sarissa Capital Management LP
16,390,000€30.0m0%8.81%
7.33%
Pacer Advisors, Inc.
11,730,771€21.5m4%0.05%
5.37%
Renaissance Technologies LLC
8,597,198€15.7m0.3%0.02%
5.2%
State Street Global Advisors, Inc.
8,328,817€15.2m-16%no data
5.12%
Armistice Capital LLC
8,200,000€15.0m5.13%0.36%
3.16%
LSV Asset Management
5,051,601€9.2m-16.8%0.02%
2.77%
Braidwell LP
4,438,232€8.1m0%0.39%
2.67%
Jacobs Levy Equity Management Inc
4,265,100€7.8m-2.14%0.03%
2.3%
Kynam Capital Management, LP
3,685,563€6.7m124%0.55%
2.3%
Morgan Stanley, Investment Banking and Brokerage Investments
3,672,661€6.7m-8.72%no data
2.06%
Geode Capital Management, LLC
3,293,542€6.0m-2.34%no data
1.24%
Charles Schwab Investment Management, Inc.
1,983,240€3.6m4.15%no data
0.94%
Northern Trust Global Investments
1,506,148€2.8m2.01%no data
0.87%
Norges Bank Investment Management
1,393,077€2.5m0%no data
0.79%
Two Sigma Advisers, LP
1,260,500€2.3m5.13%0.01%
0.76%
Jupiter Fund Management Plc
1,223,275€2.2m-15.6%0.01%
0.76%
UBS Asset Management AG
1,216,609€2.2m-43.4%no data
0.75%
Argenta Asset Management SA
1,207,997€2.2m0%0.04%
0.7%
Saturn V Capital Management LP
1,120,409€2.1m0.59%1.07%
0.66%
Deutsche Asset & Wealth Management
1,063,199€1.9m1.53%no data
0.63%
Acadian Asset Management LLC
1,014,463€1.9m29%no data
0.62%
Stonepine Capital Management LLC
1,000,000€1.8m1,980%0.68%
0.61%
BNY Asset Management
978,135€1.8m7.16%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/17 05:57
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ironwood Pharmaceuticals, Inc. is covered by 35 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Patrick TrucchioBerenberg
David MarisBMO Capital Markets Equity Research